AUG 22, 2013 7:00 AM PDT

Soluble 14-3-3? - A Personalised Rheumatoid Arthritis Patient Management Strategy

Speaker

Abstract
Rheumatoid Arthritis (RA) is a heterogenous disease that affects 1.5% of the population. Similar to cancer, early detection coupled with an effective treatment strategy can significantly improve patient outcomes. In the advent of new classes of RA therapies, there is an impetus to identify new serological markers that mark risk of RA development, prognosis and therapy response. 14-3-3 eta (?) is a new RA marker that is available for clinical use in the US through Quest Diagnostics. 14-3-3? is one of 7 members of the 14-3-3 family and is specifically present in the serum of patients with RA and erosive psoriatic arthritis (PsA). In the healthy state, these proteins reside within the intracellular space governing various biological processes including proliferation, differentiation and metabolism. Increased expression of different 14-3-3 isoforms correspond with worse prognosis in certain cancers and neurological disorders. In RA, the 14-3-3? protein is specifically externalized and can be measured in serum, making it a useful clinical serum marker. When 14-3-3? exists in the extracellular environment, it behaves as a soluble ligand inducing factors that drive inflammation and joint damage also making it a novel therapeutic target. This presentation will describe the discovery of 14-3-3? in arthritis, its development pathway and the biomarker's clinical utility. We will discuss how the 14-3-3? biomarker pipeline has evolved from the protein R&D programs into a 14-3-3? biomarker suite that serves as a direct companion to a first-in-class RA personalized medicine drug target.

Show Resources
You May Also Like
FEB 15, 2023 7:00 AM PST
FEB 15, 2023 7:00 AM PST
Date: February 15, 2023 Time: 7:00am (PST), 10:00pm (EST), 4:00pm (CET) While not all microscopy samples can fluoresce, all can scatter light, and this scattered light can be imaged. This ha...
SEP 22, 2022 9:00 AM PDT
SEP 22, 2022 9:00 AM PDT
Date: September 22, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 6:00pm (CEST) Optimizing platforms for surgical specimen collection and deep human phenotyping was used to enhance protein biomarke...
NOV 16, 2022 7:00 PM PST
C.E. CREDITS
NOV 16, 2022 7:00 PM PST
Date: November 16, 2022 Time: 2:00pm (AEST) Date: November 17, 2022 7:00pm (PST), 10:00pm (EST), 4:00am (CET) The growth in FDA-approved cell and gene therapy products for the treatment of d...
DEC 15, 2022 8:00 AM PST
DEC 15, 2022 8:00 AM PST
Date: October 26, 2022 Time: 9:00am (PST), 12:00pm (EST), 6:00pm (CEST) Current protein biomarkers are only moderately predictive in identifying individuals with mild traumatic brain injury...
AUG 24, 2022 7:00 AM PDT
AUG 24, 2022 7:00 AM PDT
Date: August 24, 2022 Time: 7:00am (PDT), 10:00pm (EDT), 4:00pm (CEST) Light field microscopy was first introduced in 2006, and allows users to capture the 4D light field within the microsco...
NOV 07, 2022 9:00 PM PST
C.E. CREDITS
NOV 07, 2022 9:00 PM PST
Date: November 8, 2022 Time: 1:00pm (SGT), 12:00pm (EST), 6:00am (CET) Antibodies are vital tools in many of the laboratory techniques that are used...
Loading Comments...
Show Resources
Attendees